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 Implication for health policy/practice/research/medical education:
This review article provides evidence gathered from published data related to the; magnitude, etiological factors, disease character-
istics, therapeutic response and survival of HCC patients in Pakistan.
Context: From the 1970s till the mid 1990s, hepatitis B was the most common etiological 
factor for hepatocellular carcinoma (HCC) in Pakistan. Afterwards, a shift in HCC etiol-
ogy was observed with a steady rise in hepatitis C virus (HCV) related HCC cases. HCV-3a, 
which is the most prevalent genotype, is also most frequent in HCV related HCC. There 
was an increase in the proportion of non-B non-C (NBNC) HCC cases as well, which might 
be attributed to an increase in non-alcoholic fatty liver disease. 
Evidence Acquisition: The age-standardized rate for HCC is 7.64/100 000 in males and 
2.8/100 000 in females. Male to female ratio is 3.6:1. Usual age of presentation is in the 
fifth and sixth decade. Most patients present with advanced disease, as they are not in a 
regular surveillance program. This is more so for patients with NBNC chronic liver dis-
ease. As many sonologists in Pakistan are practicing without sufficient training to pick 
up early lesions, alpha-fetoprotein is still recommended to compliment ultrasound in 
the surveillance of HCC. 
Results: Majority of HCC patients present with nonresectable disease. Interventions 
such as transarterial chemoembolization, radiofrequency ablation, resection and chem-
otherapy including sorafenib are available in selected centers. Pakistan appears to be in 
an area of intermediate endemicity for HCC. There is a need for population based epide-
miological studies to estimate the exact disease burden.
Conclusions: Measures to prevent the spread of hepatitis C and B can slow down the epi-
demic rise in the incidence of HCC in the coming decades. There is a need to implement 
a proper surveillance program to identify HCC cases at an early stage. 
Hepat Mon.2012;12(10 HCC): e6023. DOI: 10.5812/hepatmon.6023
1. Context
Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer globally, attributing to 626 000 or 5.7% of 
new cancer cases annually (1). It is the third most com-
mon cause of cancer related deaths globally and carries 
an overall survival rate of only 3-5%. The major burden 
of HCC lies in developing countries; up to 82% of HCC 
cases are reported from developing countries, including 
55% from China alone (1-3). Moreover, relatively high in-
cidence rates have been found in South East Asia and in 
Sub-Saharan Africa (2-4). Hepatitis B and C are the major 
risk factors for HCC (5). Geographical variations in the 
significance of hepatitis B virus (HBV) and hepatitis C vi-
rus (HCV) infections in the development of HCC, clinical 
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features and survival have been reported (1, 6, 7). Howev-
er, the evidence regarding risk estimates for the develop-
ment of HCC in individuals coinfected with HBV, HCV and 
hepatitis D (HDV) is lacking (3). 
Pakistan is located in South-Asia where the prevalence 
of hepatitis B and C is intermediate (6, 7). Considering 
the burden of hepatitis B and C, it is expected that the 
incidence of HCC will increase further in the foreseen fu-
ture, especially in countries such as China and Taiwan (8). 
Hence, HCC will be a major burden on their healthcare 
systems (3). This review is based on evidence gathered 
from published data related to the; magnitude, etiologi-
cal factors, disease characteristics, therapeutic response 
and survival of HCC patients in Pakistan.
2. Evidence Acquisition 
2.1. Search Strategy
Medline indexed database, Google Scholar and a local 
search engine, i.e. PakMediNet (http://www.pakmedinet.
com), which also lists local studies that are not listed in 
Medline) as well as abstracts from major international 
hepatology conferences, were used to search for relevant 
articles published during January 1970 till September 
2011. Mesh terms; “Hepatocellular Carcinoma and Paki-
stan”, “Hepatoma and Pakistan”, “Primary liver cancer 
and Pakistan”, “HCC and Pakistan” and “liver cancer and 
Pakistan” were used for the search. In addition, relevant 
studies were identified by reviewing the reference lists 
of selected articles. Those articles that were relevant and 
where their full text article or complete abstract was 
available and the sample size was at least 20, were includ-
ed in this review.
3. Result
3.1. Epidemiology
Unfortunately, no population based study was available 
from which a true prevalence and incidence rate of HCC 
could be ascertained. Most of the studies were hospital 
based, consisting of case series with small sample sizes or 
they had a highly select population. However, there have 
been a few cancer registries established in Pakistan. The 
Karachi Cancer Registry (KCR) was the first population-
based cancer registry, established in 1995, by the Sindh 
Government, in technical collaboration with the Unit 
of Descriptive Epidemiology, International Agency for 
Research on Cancer (IARC) of the World Health Organiza-
tion (WHO) (9). The Aga Khan University Cancer Surveil-
lance for Pakistan (ACSP) was established in 2000 at the 
Aga Khan University Pathology-based Cancer Registry 
(APCR), which covers a large geographical area and popu-
lation of Pakistan, through their 84 centers. Moreover, 
APCR is an associate member of the IACR (10). The inci-
dence and prevalence of the various cancers has been es-
timated in certain cities via these registries. Out of 4 268 
new cancer cases registered in the KCR from Karachi, dis-
trict South during 1995-1997, the age-standardized rates 
(ASR) for HCC were found to be 5.7/100 000 in males and 
3.7/100 000 in females (rank 9th) (9). Furthermore, ASR 
(world population was taken as a reference here) were 
found to be 5.3 and 4.0/100 000  in Karachi during 1998 to 
2002 (11). Moreover, among the cancers registered to KCR 
and APCR from Larkana during 2000-2002, ASR for HCC 
were 10.5/100 000 persons in male and 2.0/100 000 in fe-
males (12). Likewise, cancer patients who were residents 
of Hyderabad and who were registered in KCR and APCR 
during 1998 to 2002, their ASR for HCC were reported to 
be 4.4/100 000 in males and 1.2/100 000 in females (10). 
From Quetta, 1 077 cancers were registered in KCR during 
1998 to 1999. Here, HCC was found to be the third most 
common cancer in men (age standardized rate 12.3/100 
000) and the seventh most common cancer in women 
(ASR 3.1/100 000) (13). Hence, ASR reported an average fig-
ure in these different studies as 7.64/100 000 for males 
and 2.8/100 000 for females. Another hospital based tu-
mor registry has been established at the Armed Forces In-
stitute of Pathology (AFIP). Out of 21 168 cancers reviewed 
during 1992-2001, liver cancers were found in 22 (2.81%) 
males and 22 (2.81%) females (14). 
Besides these registered data, 29 relevant studies were 
found where the epidemiological aspects of HCC were 
evaluated (Table 1). The numbers of cases from these 29 
studies were aggregated (n = 3319) and trends of HCC, gen-
der distribution and etiological factors were analyzed. 
Out of the 3 319 cases, information regarding gender was 
available for 2 967 cases. Out of 2 967 cases, 78.29% were 
male and 21.71% were female. Age ranges were between 
8-98 years. However, in most of the studies HCC cases pre-
sented during the fifth decade of life. Information about 
the etiological factors for HCC was available in 2 852 cases; 
HCV, HBV and HCV/HBV co-infection was found in 57.99%, 
25.35% and 5.26% cases respectively. Coinfection with HBV 
and HDV was found in 1.09% cases and hepatitis B/C/D co-
infection was found in 0.63% cases. Moreover, 9.68% cases 
were seronegative for hepatitis B and C (NBNC-HCC). As 
it is clear from Figure 1, the number of studies related to 
HCC increased with the passage of time. Hence, a rise in 
the number of HCC cases was observed during the study 
period. During the entire study, an almost consistent 
male preponderance was found in the HCC cases. As far 
as the etiology of HCC is concerned, it has been identi-
fied that from the 1970s till the mid 1990s, hepatitis B 
was the most common etiological factor for HCC. After-
wards, a shift in HCC etiology with a steady rise in HCV 
related HCC cases were observed (Figure 2). Moreover, an 
inconsistent rise in the number of HCC cases attributed 
to HBV/HCV or HCV/HBV/HDV co-infection and NBNC-HCC 
was also recognized (Figure 3). To evaluate the data fur-
ther, we divided the time period into three categories; 1. 
1970-1999 2. 2000-2005 and 3. 2006-2011, and the data was 
compared for these different time periods (Table 2). Again 
a clear, consistent shift was recognized in the etiology of 
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HCC (Figure 4). Replacement of HBV by HCV as the major 
etiological factor for HCC was quite clear. Moreover, a 
rising trend was seen in the number of NBNC-HCC cases 
during these time periods. Hence, viral hepatitis is identi-
fied as the major attributable factor of HCC in Pakistan. 
Hepatitis C followed by hepatitis B, HBV/HCV coinfection 
and HBV/HDV coinfection are the foremost factors lead-
ing to HCC. Considering the increasing prevalence of 
diabetes, hypertension and dyslipidemia in Pakistan, we 
can assume that the rising numbers of NBNC-HCC might 
be attributed to non-alcoholic fatty liver disease (NAFLD) 
which requires further studies for confirmation. Further-
more, in Pakistan, a high rate of food contamination with 
aflatoxin has been reported earlier, and this is a known 
carcinogen for HCC in humans (15, 16). However, there is 
a lack of data regarding aflatoxins leading to HCC from 
Pakistan. 
3.2. HCV Genotypes and HCC
Hepatitis C is the commonest cause of HCC in most of 
the developing countries and the distribution of HCV 
genotypes varies across the world. Hence, studies have 
been conducted in different populations worldwide to 
evaluate the association of HCV genotype 1 with HCC de-
velopment.  In Pakistan, the most prevalent HCV genotype 
is 3. Until now, only two studies have been conducted in 
Pakistan to study the association of HCV genotypes with 
HCC. Khan A et al. (17) evaluated 189 patients with chronic 
liver disease including 82 with HCC.  Hepatitis C genotype 
3a was the predominant genotype (81.4%) followed by 3b 
(9.3%), 3k (2.3%), 1a (1.5%), 1c (1.5%), 1b (0.8%), and 2a (0.8%). 
Out of 82 HCC cases, 76% were infected with genotype 3a. 
However, considering the small sample size this study 
lacks the strength to correlate other HCV genotypes with 
HCC in our population. The additional information that 
was provided by the study from Khan et al. (17), is the exis-
tence of a distinct phylogenetic cluster of genotype 3a in 
Pakistan, and its appearance in this region in 1920s had 
a rapid exponential growth in the 1950s. Hence, these 
findings suggest an earlier epidemic spread of HCV-3a 
in Pakistan than in the other countries where genotype 
3 has been reported. This might be associated with the 
increasing incidence of HCC in Pakistan during the last 
few decades.  Likewise, in another study the distribution 
of the HCV genotype found was; 3a in 40.96%, 3b in 15.66%, 
1a in 9.63%, and 1b in 2.40% and mixed genotypes in 28.91% 
of HCC patients. Of the 24 mixed genotypes, ten were in-
fected with genotypes 3a and 3b, eight with 1a and 3a, and 
six with 1a and 3b. While, two tissue samples were found 
to be untypable as no genotype was detected (37).
3.3. Clinical Presentations of HCC
Most of the available studies have emphasized the epi-
demiological aspects. In general most of the patients 
remained; asymptomatic or experienced right hypo-
chondrial pain, weight loss, jaundice, fever, upper gas-
trointestinal bleed, hepatic encephalopathy, hepato-
splenomegaly, abdominal/liver mass and ascites (18-23). 
Cirrhosis was reported in 69-84% cases with Child’s class 
B or C in most of the cases (18, 21-25). Out of 400 HCC cases 
reviewed by Yusuf et al. (26) 216, 147 and 37 patients had 
Child’s class A, B and C respectively. Whilst in another 
study, out of 645 HCC cases, the majority had Child’s class 
B (42.3%) or C (45.1%) cirrhosis (27).
Furthermore, it was an alarming finding that 82.9% of 
the HCC cases in the largest case series of 645 patients 
were diagnosed when they were symptomatic and 8.8% 
Figure 1. Distribution of HCC Cases, 1970-2011
Figure 2. Comparison  of  Hepatitis  B  and  C  Related HCC and NBNC-HCC
During 1970-2011
Figure 3. Comparison of Various Etiological Factors for HCC, 1970-2011
Figure 4. Comparison of Hepatitis B and C related HCC and NBNC-HCC 
during Different Time Intervals
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Year Sample Size Male Female HBsAg+ Anti-HCV+ HBSAg + & HCV+ HBsAg- & HCV- HBV+ & HDV+ B & C & D+
1970-1999 283 99 18 81 85 24 20 11 0
2000-2005 791 452 153 206 353 43 94 0 0
2006-2011 2245 1772 473 436 1216 83 162 20 18
Table 2. HCC Cases during Different Time Periods
Sample Size Mean ± SD or Median Range Others, ng/ml Elevated AFP, %
Butt AK, et al. 1998 (21) 76 142 ± 155 2.7-1470 - -
Shah GG, et al. 1999 (53) 32 - - - 84.3
Khokhar N, 2001, et al. (22) 27 - 43-6300 -
Chohan Arm, et al. 2001 (18) 30 - - - 63.3
Sharieff  S, et al. 2001 (32) 201 17,027 ± 68, 853 - > 1000: 35% 35
Normal AFP: 24%
Khokar N, et al. 2003 (24) 67 632.09 ± 1332.31 - - 80
Gill ML, et al. 2005 (36) 22 15000 ± 1000 - -
Ziauddin, et al. 2006 (50) 52 - -  < 200:13.5% 100
200-400:25%
> 400;61.5%
Yusuf MA, et al. 2007 (26) 442 4198 ± 262 (median) 1-278,560 > 200:70% -
Abbas Z, et al. 2008 (35) 129 > 400:37.5% 31
Baig JA, et al. 2009 (51) 39 421 ± 59 101–2341 - -
Ali R, et al. 2010 (19) 114 - - < 100:7% 72.8
> 100 :10.5%
≥ 500:5.3%
Abbasi AB, et al. 2010 (20) 82 2582.52 2.54- 65609 ≥ 400 in 46.34% -
Butt AS, et al. 2011 (27) 645 82.0 (median) 0.95-303717 ≥ 20:65.7% 67.5
≥ 200:41.2%
Table 3. Alpha-Fetoprotein (AFP) Levels in Patients With HCC
were diagnosed incidentally. Whereas, only 8.2% (n = 53) 
of the HCC cases were diagnosed on screening. The dura-
tion between diagnosis of a chronic liver disease and HCC 
was 24.01 ± 38.05 months (range 0-195 months). More-
over, 480 (74.4%) patients experienced at least one com-
plication related to cirrhosis earlier to their index presen-
tation, and that included; ascites (68.5%), portosystemic 
encephalopathy (34.1%), esophageal varices (53%), upper 
gastrointestinal bleeding (40.5%), hepatorenal syndrome 
(22.6%), hepatohydrothorax (9%), hepatopulmonary syn-
drome (7.8%) and hypersplenism (62.2%). Among all of 
the patients, 259 (40.2%), 222 (34.4%) and 16 (2.5%) had 
concomitant diabetes, hypertension or dyslipidemia re-
spectively (27). In some studies HBV-related HCC patients 
were found to be younger than HCV-related HCC patients 
(49.7 v/s 56.3 years) (28). Elevated serum bilirubin (100%), 
alanine aminotransferase (ALT) (42.1%), aspartate amino-
transferase (AST) (42.1%), and alkaline phosphatase (100%), 
were reported in a group of 145 patients (25). Hence, most 
of the patients presented with an advanced disease stage, 
as they were not under a regular surveillance program. 
This was even true for patients with NBNC chronic liver 
disease leading to HCC (27). In the process of comparing 
HCC in HBV mono-infection with HBV/HDV co-infection, 
it was later found to be associated with a smaller liver size 
and indirect evidence of more severe portal hyperten-
sion in an earlier TNM stage (29).
3.4. Diagnosis of HCC
3.4.1. Alpha-Fetoprotein
Alpha-fetoprotein (α-fetoprotein, AFP) is a large serum 
glycoprotein, used as a tumor marker for HCC. The sum-
mary of AFP in various studies is given in Table 3. A wide 
variability in ranges of AFP was found in the various stud-
ies. Elevated AFP was reported in 31-100% cases. However, 
AFP > 200 or > 400 ng/ml was found to be associated with 
a greater accuracy in detecting HCC. The diagnostic value 
of  AFP for HCC, was evaluated among 100 biopsy proven 
HCC cases and 100 healthy subjects, who were found to 
Hepat Mon. 2012;12(10 HCC): e6023
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Sample Size Tumor Diameter Mean ±SD, cm No. of Lesion Others 
Butt AK, et al. 1998 (21) 76 7.8 × 8.1 Solitary: 54% > 8cm: 54%
Multifocal/diffuse : 46%
Shah GG, et al. 1999 (53) 32 Diffuse: 38% > 10 cm: 31.2%
Right  lobe involved 
predominantly
Sharieff  S, et al. 2001 (32) 201 8.3 ± 4.0 - > 5cm: 79.49%
Khokhar N, et al. 2001 (22) 27 Single: 63% -
Multiple: 37%
Khokar N, et al. 2003 (24) 67 6.6 ± 1.14 Single: 49% Rt /left lobe involved: 
3/7 
Multiple: 51%
Yaqoob J, et al. 2004 (34) 40 3.1 Single: 13 cases Range for tumor size: 
0.8 to 14
Multifocal: 13 cases
Dominant mass with 
satellite lesions: 12
Cluster of contiguous 
nodules: 2
Gill ML, et al. 2005 (36) 22 5.0 ± 1.0
Ziauddin , et al. 2006 (50) 52 5.41 > 10cm 15.4% Rt/left/both lobes in-
volved: 44.2%/5.8%/50%
5.1-10cm -28.8%
2-5cm -55.8%
Yusuf MA, et al. 2007 (26) 497 8 Solitary: 33%
Multifocal: 52%
Ansari S, et al. 2009 (23) 200 Single (< 5cm): 30% PVT: 18%
Single (> 5cm): 19.5%
Multicentric: 68.34%
Abbasi AB, et al. 2010 (20) 82 Single: 68.29% PVT: 24.39%
Multiple: 26.82% > 50% liver involved : 
51.21%
Diffuse : 4.87%
Butt AS, et al. 2011 (27) 645 5.62 ± 3.67 Solitary: 38.1% < 5 cm in 55.7%
Paucifocal: 40.2% 5-10cm in 33%
Multifocal: 14.9% > 10cm in 11.3% 
Massive/infiltrative: 6.8% PVT: 33.5%
Extrahepatic spread : 
13.2%
Rt/left/both 
lobes:60%/12.3/27.5
Table 4. Radiological Features of HCC
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be HBsAg positive on blood screening (30). AFP was found 
with 72% sensitivity, 89% specificity, 86.7% positive predic-
tive value, and 76.1% negative predictive value to detect 
HCC (P < 0.001). Likewise in another study (n = 100), AFP 
was found to be 72% sensitive and, 89% specific to detect 
HCC (31). However, no correlation was found between the 
size of the HCC and AFP levels when assessed in 201 pa-
tients (r = -0.155; P = 0.129) (32). There is much debate now-
adays about the value of AFP in a surveillance program 
for HCC. What we have observed here in Pakistan is that 
many sonologists are practicing with  insufficient train-
ing to pick up early lesions. Hence, alpha-fetoprotein is 
generally used as a screening tumor marker to compli-
ment ultrasound liver tests for the surveillance of HCC.
3.4.2. Radiological Features of HCC
The presence of arterial enhancement, followed by 
washout of contrast in the portal-venous and delayed 
phase, are considered to be typical characteristic features 
of HCC (19, 33). Tumor size, number of lesions, local or 
distant metastasis are all prognostic factors and these 
help to make a decision about treatment. A summary of 
the various studies which describe radiological charac-
teristics of HCC are given in Table 4. The role of biphasic 
contrast-enhanced helical CT including hepatic arterial 
phase (HAP) with portal venous phase (PVP) imaging, in 
the detection and characterization of HCC was evaluated 
by Yaqoob J et al. in 40 biopsy proven, HCC cases (34). The 
detection rate for HCC was 85% with HAP imaging (hyper-
attenuating = 69, hypoattenuating = 3) when compared 
to 48% with PVP imaging (hyperattenuating = 2, hypoat-
tenuating = 39) (P = 0.008. Moreover, in 7 (17%) cases HCC 
was visible only in the HAP images. 
3.4.3. Liver Biopsy
For the diagnosis of HCC, procedures such as; AFP, liver 
biopsy, triphasic CT scan and ultrasound of the abdo-
men have been evaluated in various studies. In a study 
by Yusuf et al. (26) these different diagnostic modalities 
were evaluated for HCC. Out of 584 patients, fine needle 
aspiration (FNA) of the liver lesion was done in 71 cases, a 
core biopsy in 26 and a lipoidal angiography was carried 
out in 42 patients. A combination of typical radiological 
findings on an imaging modality and an elevated AFP (> 
200 ng/ml) was found in 70 patients. Moreover, a combi-
nation of at least two of these modalities, i.e. characteris-
tic findings on a triphasic CT scan, AFP level > 200ng/ml 
and positive cytology or histology) was reported in 365 
patients. FNA under ultrasound guidance was studied in 
60 patients with suspected HCC. Mortality was reported 
in two cases secondary to uncontrollable bleeding after 
the procedure (21). In another study, out of 114 patients 
with suspected HCC, 48 (42.1%) patients were found to 
have biopsy proven HCC. Histologically, well differenti-
ated, moderately differentiated, poorly differentiated, la-
mellar HCC were reported in 26.4%, 34.5%, 30.9% and 8.2% 
patients respectively (27).
3.5. Staging and Prognostic Factors for Survival
Different staging systems have been used in different 
studies. In a study of 76 patients 22%, 61% and 17% were 
found to have Okuda stage I, II and III respectively (20). 
Abbas Z et al. (35) estimated the survival of 129 HCC pa-
tients. Median follow up was 11 months (range 2-36). 
Three patients were lost to follow-up. Cumulative deaths 
reported at six months, one year and at two years were; 
22 (21.6%), 62 (60.8%) and 93 (92.2%) respectively. On uni-
variate analysis; hepatitis C as etiology, female gender, 
presence of ascites, splenomegaly, splenic varices, INR > 
1.3, total bilirubin > 1.17 mg/dl, direct bilirubin > 0.4 mg/
dl, alkaline phosphatase > 169 IU/L, Model for End-Stage 
Liver Disease (MELD) Score > 12, Child class B & C, multifo-
cal tumor, and transarterial chemoembolization (TACE) 
were not offered factors found to be associated with poor 
survival. However, on multivariate analysis, the overall 
independent determinants of poor survival were; hepa-
titis C as etiology, female sex and multifocality of tumor 
(hazard ratios 3.0, 3.0 and 1.9 respectively). Mean survival 
was 17.2 months for patients who underwent a TACE pro-
cedure, as compared to 12.8 months for those who did not 
receive TACE (P = 0.015). Okuda, Cancer of the Liver Ital-
ian Program (CLIP), Barcelona Clinic Liver Cancer (BCLC), 
Chinese University Prognostic Index (CUPI) and Child’s 
staging systems retained their performance as judged 
by chi-square values in a regression analysis. Discrimina-
tory ability for death, evaluated by the receiver operating 
characteristic curve, was better for the Okuda classifica-
tion system in the first year.
3.6. Treatment and Survival
Unfortunately fewer studies were available regarding 
the treatment of HCC from Pakistan. In general, data re-
garding outcomes after curative therapies, i.e. liver trans-
plantation, hepatic resection and radio frequency abla-
tion, is not available. However, scanty data is available 
concerning the various palliative therapies. In a study 
by Yusuf et al. (12), only 79 out of 584 patients were found 
to be eligible for different modalities of treatment. Out 
of the 79, 48 patients underwent transarterial chemo-
embolization (TACE) using lipiodol and doxorubicin. Of 
these, 26 had disease progression, 11 had a stable disease 
state for a minimum of six months (range 6 - 20 months), 
and 11 patients were lost to follow-up. Local resection 
was done in 14 patients and 5 remained disease free for 
an average of 33 months. Percutaneous ethanol injection 
(PEI) was performed in 17 patients. Of these, 5 progressed 
within three months of treatment, 2 had a stable disease 
state for a mean of 13 months and 10 were lost to follow-
up. Four patients underwent TACE followed by surgical 
resection. The overall median survival was 10.5 months. 
The cumulative probability of survival was 45%, 20% and 
10% at 1-year, 3-years and 5-years. Median survival was bet-
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ter for patients with Child’s class A (12 months) when 
compared to Child’s B (7.7 months) and Child’s C (4.1%). 
Moreover, the difference in median survival between pa-
tients with Child’s class A and B, or A and C was statisti-
cally significant (P < 0.001) (26). In the study by Abbas Z 
et al. (35), 41 HCC patients underwent a TACE procedure. 
Overall the median survival rate was better for patients 
offered vs. not offered TACE (14.0 months vs. 9.5 months, 
OR 1.63, 95% confidence interval 1.07-2.48, P < 0.05). TACE 
was found to be an effective palliative therapy in another 
group of 35 patients with unresectable HCC. The median 
survival time was 410 days. Moreover, a significant differ-
ence in mean survival time was found among the differ-
ent Child’s classes (p-value 0.002) (14). In another study 
of 201 patients, the median survival reported was only 16 
weeks (28). Correlation between AFP level and survival 
was evaluated further. Survival was 17.6 ± 11.5 weeks for 
patients with an AFP level less than 10 ng/ml, 17.9 ± 21.7 
weeks for patients with AFP levels between 10 to 1 000 ng/ml 
and 13.2 ± 15.6 weeks for patients with an AFP level > 1 000 ng/
ml. However, this difference was not statistically significant. 
Moreover, no difference in survival rates was found for 
HBV or HCV related HCC (32). 
Somatostatin receptors have been identified in HCC. 
Hence, long acting octreotide (LAR) has been tried in 
the  treatment of HCC. In 2003, Gill et al. (36) evaluated 
the efficacy of LAR in the treatment of  inoperable HCC 
in 22 patients, and the 20 patients who had refused the 
treatment were used as controls. Patients received 100 
mcg octreotide (subcutaneously) thrice daily for two 
weeks, followed by monthly administration of 20 mg in-
tramuscular octreotide. A total of 19 patients completed 
the six month treatment. Regression in tumor size and 
reduction in mean AFP levels were reported in 45.5% and 
50% of the cases respectively. Moreover, improvement 
in the quality of life at the end of treatment was seen in 
45.5% cases. At the end of the six month treatment, 64% 
of the patients were alive in the intervention group as 
compared to 50% in the control group. In another study 
conducted by Frooqi et al. (37), 13 advanced HCC cases 
were randomized to receive either 250 ug subcutane-
ous octreotide twice daily (6 patients) or no treatment 
(7 patients). Significant improvement in the quality of 
life amongst the treatment group was observed, as com-
pared to the control group (P < 0.05). In both studies, the 
authors recommended octreotide as an alternative for 
the treatment of inoperable HCC. However, both studies 
lacked the power to conclude that octreotide had a ben-
eficial effect, due to the small sample sizes and possible 
selection bias. In a small series of 76 patients, 22 patients 
received intralesional alcohol injections. However, 54% of 
these patients with a tumor size > 8 cm died during fol-
low up; this was due to liver failure in 8 cases and fatal 
bleeding occurred in 4 patients (21). In a study done by 
Anis et al., oral capecitabine monotherapy failed to halt 
tumor growth in advanced hepatocellular carcinoma 
(38). In general, studies regarding the curative treat-
ment of HCC are not available. There are only a few cases 
that underwent resection of HCC which has been men-
tioned in several studies. Current existing data regarding 
treatment and prognosis carries the limitation of small 
sample size; it is mainly based upon single center experi-
ences and lack of proper follow-ups. Hence, reporting the 
results of curative and various palliative treatment mo-
dalities will provide evidence regarding the outcome and 
natural history of our HCC cases. 
4. Conclusion
Hepatitis C related chronic liver disease has become the 
major cause of a rising prevalence of HCC in Pakistan. 
The country appears to be in an area of intermediate en-
demicity for HCC. There is a need for population based 
epidemiological studies to estimate the exact disease 
burden. Measures to prevent the spread of hepatitis C 
and B can slow down the epidemic rise in the incidence 
in the coming decades. There is a need to implement a 
proper surveillance program to pick up the disease ear-
ly. Treatment facilities are not widely available as data 
about treatment outcomes is scarce. The availability of 
a sufficient number of patients opens opportunities to 
do translational research, however, this is lacking at the 
moment.
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